Coral Laboratories logo

Coral Laboratories

CORALLABORATORIESLTD NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹209 Cr
Volatility
Moderate
P/E Ratio
10.4
EBITDA
₹25.10 Cr
Return on Equity
7.83%
Debt to Equity
0.02
Book Value
₹585.74
EPS
₹44.58
52W High
₹679
52W Low
₹360

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company is almost debt free.
  • Stock is trading at 1.00 times its book value

Weaknesses

3
  • The company has delivered a poor sales growth of -2.31% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Earnings include an other income of Rs.10.3 Cr.

Growth Rate

Revenue Growth
-22.8% lower than 3Y
Net Income Growth
-32.23% lower than 3Y
Cash Flow Change
77.66% higher than 3Y
ROE
-34.8% lower than 3Y
ROCE
-31.51% lower than 3Y
EBITDA Margin (Avg.)
-7.97% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
13.55
23.15
18.08
28.89
31.66
32.23
22.99
28.13
18.82
19.03
21.56
26.48
29.62
Expenses
11.81
17
15.98
22.64
20.92
25.72
16.67
25.44
16.64
14.09
19.67
20.28
24.13
Operating Profit
1.74
6.15
2.1
6.25
10.74
6.51
6.32
2.69
2.18
4.94
1.89
6.2
5.49
OPM %
12.84%
26.57%
11.62%
21.63%
33.92%
20.2%
27.49%
9.56%
11.58%
25.96%
8.77%
23.41%
18.53%
Other Income
1.29
1.81
1.37
2
1.56
2.54
2.52
1.71
2.05
3.03
2.49
2.64
2.15
Interest
0
0
0
0
0.03
0.01
0.02
0.04
0.06
0.1
0
0.01
0.03
Depreciation
0.55
0.44
0.49
0.5
0.49
0.51
0.5
0.51
0.45
0.45
0.69
0.54
0.66
PBT
2.48
7.52
2.98
7.75
11.78
8.53
8.32
3.85
3.72
7.42
3.69
8.29
6.95
Tax %
26.21%
20.21%
27.52%
25.16%
25.21%
25.21%
26.08%
26.49%
31.18%
21.56%
24.93%
36.91%
22.45%
Net Profit
1.84
6
2.16
5.79
8.8
6.38
6.14
2.83
2.56
5.82
2.78
5.22
5.39
EPS in Rs
5.15
16.79
6.05
16.21
24.63
17.86
17.19
7.92
7.17
16.29
7.78
14.61
15.09
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
59
77
95
92
91
71
97
76
78
84
115
86
97
Expenses
47
60
72
77
79
65
81
67
74
67
89
71
78
Operating Profit
12
16
23
15
12
5
16
8
4
16
26
15
19
OPM %
21%
21%
24%
17%
14%
8%
16%
11%
4.9%
19%
23%
18%
19%
Other Income
3
3
3
4
5
6
4
6
7
6
8
10
10
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
3
2
2
2
2
2
2
2
2
2
2
2
2
PBT
12
17
25
18
16
9
18
12
8
21
32
23
26
Tax %
22%
29%
34%
31%
34%
22%
23%
24%
22%
24%
26%
29%
—
Net Profit
10
12
16
12
10
7
14
9
6
16
24
16
19
EPS in Rs
26.79
34.71
45.63
34.85
28.61
19.96
37.93
25.33
18.05
44.2
67.63
45.85
53.77
Div. Payout %
9%
9%
11%
6%
7%
0%
0%
0%
0%
0%
2%
4%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
4
4
4
4
4
4
4
4
4
4
4
Reserves
56
67
106
113
110
112
133
152
151
174
198
206
Borrowings
1
0
2
2
1
6
6
6
0
0
4
4
Other Liabilities
12
19
20
22
21
23
25
28
20
28
25
27
Total Liabilities
72
89
131
140
136
144
168
190
174
206
229
241
Fixed Assets
19
18
18
22
23
23
21
24
25
24
23
44
CWIP
0
0
0
0
0
0
0
2
0
0
2
0
Investments
1
5
39
45
28
25
33
46
41
50
52
46
Other Assets
52
67
74
73
84
97
112
118
108
132
152
150
Total Assets
72
89
131
140
136
144
168
190
174
206
229
241
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
5
11
13
-1
-4
1
6
13
-5
-1
16
Investing
0
-3
-10
-13
3
-2
0
-6
-3
1
0
-18
Financing
0
0
0
-3
-1
4
0
0
-6
0
3
0
Net Cash Flow
0
2
1
-2
1
-2
1
0
4
-4
1
-2
Free Cash Flow
-1
4
9
9
-4
-5
0
1
11
-6
-4
-5
CFO/OP
30
70
85
124
31
-59
28
127
383
-4
23
150
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
152
132
117
125
122
178
148
184
109
123
107
125
Inventory Days
110
110
155
120
116
176
158
169
100
149
68
211
Days Payable
66
80
75
87
91
129
108
81
34
130
46
103
Cash Conversion Cycle
196
162
197
157
146
225
198
272
176
142
129
233
Working Capital Days
194
179
164
161
171
241
178
222
221
183
140
203
ROCE %
22%
27%
28%
16%
13%
8%
13%
7%
5%
13%
17%
11%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Coral Laboratories insights

64 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Shareholding Pattern

Promot.71.51%Others8.56%Public19.93%As ofJun 2026

Documents

Frequently Asked Questions about Coral Laboratories

What does Coral Laboratories Ltd do?
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]
Where is Coral Laboratories Ltd (524506) listed?
Coral Laboratories Ltd trades as CORALLABORATORIESLTD on the NSE and under code CORALAB on the BSE.
Which sector does Coral Laboratories Ltd belong to?
Coral Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Coral Laboratories Ltd?
Coral Laboratories Ltd has a market capitalisation of ₹209.22 Cr, which places it in the Small Cap band.
What is the PE ratio of Coral Laboratories Ltd?
Coral Laboratories Ltd trades at a PE ratio of 10.40, on earnings per share of ₹44.58, against a book value of ₹585.74 per share.
What is the 52-week high and low of Coral Laboratories Ltd?
Over the last 52 weeks Coral Laboratories Ltd has traded between ₹360 and ₹679.
Does Coral Laboratories Ltd pay dividends?
Coral Laboratories Ltd has a dividend yield of 0.36%.
What is the Return on Equity (ROE) of Coral Laboratories Ltd?
Coral Laboratories Ltd reported a return on equity of 7.83%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]

Website corallab.com
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524506.md for Coral Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List